2010 Scrip 100 - Strengthening Bayer Schering Pharma's franchise selectively
This article was originally published in Scrip
Executive Summary
A strong, late-stage pipeline, good penetration of emerging markets and a relatively low exposure in the US have made Bayer Schering Pharma one of the more interesting of the leading pharma companies to watch. Its CEO Andreas Fibig talked to Ashley Yeo.